Apparatus

The Fraunhofer Institute in Germany has now developed two techniques that could make testing faster and cheaper.

Biopharmaceutical company Airway has announced that the first patient will be administered AT-100 (rhSP-D) in a phase 1b randomised trial to prevent the risk of bronchopulmonary dysplasia (BPD) in very preterm infants. The novel prophylactic AT-100 reduces the incidence and severity of the severe respiratory disease BPD and may improve the prognosis of very preterm infants.

As more and more organisms become resistant to antibiotics, the threat to human health is increasing. The overuse of antibiotics leads to drug resistance. It is very important to limit the use of antibiotics. The research team of the University of Alberta in Canada has recently developed a hand-held detection instrument, which allows first-line clinicians to distinguish between patients with viral infection or bacterial infection within a few minutes, thus helping to reduce unnecessary antibiotic prescriptions and overuse of antibiotics. Because antibiotics are only effective for bacteria, if the patient is infected with virus, there is no need to prescribe antibiotics.

The global ADC drug market will be approximately $5.2 billion by 2021

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

The US FDA has accelerated the approval of the new drug Pirtobrutinib for the treatment of relapsed or refractory set of cell lymphomas. The drug led to substantial tumour disappearance in 50% of patients, with 13% of them having complete tumour disappearance.

HBM1020 is the world's first anti-B7H7 monoclonal antibody to be formally approved for clinical phase.

Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."

Was the omission of key data intentional or unintentional?

Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.